Innoforce Pharmaceuticals, a biopharmaceutical innovation and partnership company, announced today the completion of a 625M CNY ($96M) Series A financing, which follows a 170M CNY ($24M) Pre-A financing completed in June 2020.
Innoforce and dMed have signed an agreement under which the two parties agreed to establish a partnership to identify, assess, and collaborate on the development of clinical-stage therapeutics.
Thermo Fisher Scientific and Innoforce have signed a joint venture agreement to establish a new pharma services facility in Hangzhou, China, for integrated biologics and steriles drug development and manufacturing.